关键词

白细胞介素 司库奇尤单抗 免疫 单克隆抗体 幽门螺旋杆菌 白细胞介素-2 维奈托克 替雷利珠单抗

 

#今日行业热点#

①The Lancet Rheumatology：Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial

临床试验：靶向白细胞介素- 17A的单克隆抗体司库奇尤单抗（Secukinumab）在巨细胞动脉炎(TitAIN)患者的随机、双盲、安慰剂对照、Ⅱ期试验

DOI: 10.1016/S2665-9913(23)00101-7

②The Lancet Rheumatology：Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study

临床研究：既往类风湿关节炎患者接受免疫检查点抑制剂用于癌症后的死亡率和免疫相关不良事件

DOI:10.1016/S2665-9913(23)00064-4

③Nature Communications：A blocking monoclonal antibody reveals dimerization of intracellular domains of ALK2 associated with genetic disorders

阻断性单克隆抗体揭示与遗传性疾病相关的激活素受体样激酶2 (ALK2)胞内结构域的二聚化

DOI: 10.1038/s41467-023-38746-5

④Cell Reports：Helicobacter spp. are prevalent in wild mice and protect from lethal Citrobacterrodentium infection in the absence of adaptive immunity

幽门螺杆菌在野生小鼠中富集，并在缺乏适应性免疫的情况下保护小鼠免受致命性柠檬酸杆菌感染

DOI: 10.1016/j.celrep.2023.112549

⑤Journal of Neurology:A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis

临床试验：低剂量白细胞介素-2 (interleukin-2, IL2LD)用于复发缓解型多发性硬化的随机双盲安慰剂对照试验

DOI: 10.1007/s00415-023-11690-6

⑥Expert Opinion on Pharmacotherapy：An update on the efficacy of Venetoclax for chronic lymphocytic leukemia

综述：BCL2选择性抑制剂维奈托克(Venetoclax)用于慢性淋巴细胞白血病(CLL)领域的最新进展

DOI: 10.1080/14656566.2023.2218545

⑦替雷利珠单抗用于广泛期小细胞肺癌患者的Ⅲ期临床试验达到主要终点

⑧美国Neuralink脑机接口试验已获得美国食品药品监督管理局（FDA）批准，将启动首次人体临床研究

⑨重组抗 IL-17 单克隆抗体SCT650C获得澳大利亚Ia期新药临床试验许可，用于中重度斑块状银屑病

⑩高选择性血管内皮生长因子受体(“VEGFR”)-1、-2及-3抑制剂呋喹替尼(Fruquintinib)用于转移性结直肠癌的新药上市申请获FDA受理并予以优先审评

 

科学探索的世界充满挑战，AtaGenix致敬每一位拓荒者，更致力于成为您信赖的合作伙伴！